Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 110

1.

Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.

Muqbil I, Chaker M, Aboukameel A, Mohammad RM, Azmi AS, Ramchandren R.

Heliyon. 2019 Aug 31;5(8):e02290. doi: 10.1016/j.heliyon.2019.e02290. eCollection 2019 Aug.

2.

DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma.

Azmi AS, Li Y, Aboukameel A, Muqbil I, Philip PA, Mohammad RM.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1101. doi: 10.3390/cancers11081101.

3.

KRASG12C inhibitors on the horizon.

Cagir A, Azmi AS.

Future Med Chem. 2019 May;11(9):923-925. doi: 10.4155/fmc-2018-0304. Epub 2019 May 29. No abstract available.

4.

Ras and exosome signaling.

Sexton RE, Mpilla G, Kim S, Philip PA, Azmi AS.

Semin Cancer Biol. 2019 Feb;54:131-137. doi: 10.1016/j.semcancer.2019.02.004. Epub 2019 Feb 12. Review.

PMID:
30769101
5.

miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma.

Tesfaye AA, Azmi AS, Philip PA.

Am J Pathol. 2019 Jan;189(1):58-70. doi: 10.1016/j.ajpath.2018.10.005. Review.

PMID:
30558723
6.

Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression.

Aboukameel A, Muqbil I, Baloglu E, Senapedis W, Landesman Y, Argueta C, Kauffman M, Chang H, Kashyap T, Shacham S, Neggers JE, Daelemans D, Heath EI, Azmi AS.

Oncotarget. 2018 Oct 19;9(82):35327-35342. doi: 10.18632/oncotarget.26239. eCollection 2018 Oct 19.

7.

Nuclear export mechanisms of circular RNAs: size does matter.

Azmi AS.

Noncoding RNA Investig. 2018 Sep;2. pii: 52. doi: 10.21037/ncri.2018.08.03. Epub 2018 Sep 14. No abstract available.

8.

Some chinks in RAS armor.

Azmi AS.

Semin Cancer Biol. 2019 Feb;54:iii-iv. doi: 10.1016/j.semcancer.2018.08.005. Epub 2018 Aug 6. No abstract available.

PMID:
30092255
9.

Nuclear Export Inhibition for Pancreatic Cancer Therapy.

Muqbil I, Azmi AS, Mohammad RM.

Cancers (Basel). 2018 May 7;10(5). pii: E138. doi: 10.3390/cancers10050138. Review.

10.

Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers.

Gawde KA, Sau S, Tatiparti K, Kashaw SK, Mehrmohammadi M, Azmi AS, Iyer AK.

Colloids Surf B Biointerfaces. 2018 Jul 1;167:8-19. doi: 10.1016/j.colsurfb.2018.03.046. Epub 2018 Mar 28.

PMID:
29625422
11.

Retraction notice to "Notch-1 induces Epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells".

Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, Banerjee S, Azmi AS, Miele L, Sarkar FH.

Cancer Lett. 2018 Jun 1;423:153. doi: 10.1016/j.canlet.2018.03.020.

12.

Rho GTPase effectors and NAD metabolism in cancer immune suppression.

Chaker M, Minden A, Chen S, Weiss RH, Chini EN, Mahipal A, Azmi AS.

Expert Opin Ther Targets. 2018 Jan;22(1):9-17. doi: 10.1080/14728222.2018.1413091. Epub 2017 Dec 10. Review.

13.

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration.

Azmi AS, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman MG, Philip PA, Mohammad RM.

Oncotarget. 2017 Jul 17;8(47):82144-82155. doi: 10.18632/oncotarget.19285. eCollection 2017 Oct 10.

14.

Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.

Mohammad RM, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Philip PA, Azmi AS.

Small GTPases. 2019 Sep;10(5):367-377. doi: 10.1080/21541248.2017.1329694. Epub 2017 Jun 23.

PMID:
28641032
15.

Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.

Ning C, Liang M, Liu S, Wang G, Edwards H, Xia Y, Polin L, Dyson G, Taub JW, Mohammad RM, Azmi AS, Zhao L, Ge Y.

Oncotarget. 2017 Jul 4;8(27):44295-44311. doi: 10.18632/oncotarget.17869.

16.

Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.

Aboukameel A, Muqbil I, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman M, Philip PA, Mohammad RM, Azmi AS.

Mol Cancer Ther. 2017 Jan;16(1):76-87. doi: 10.1158/1535-7163.MCT-16-0205. Epub 2016 Nov 15.

17.

Targeting Cancer at the Nuclear Pore.

Azmi AS, Mohammad RM.

J Clin Oncol. 2016 Dec;34(34):4180-4182. Epub 2016 Oct 23. No abstract available.

PMID:
27863200
18.

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.

Muqbil I, Aboukameel A, Elloul S, Carlson R, Senapedis W, Baloglu E, Kauffman M, Shacham S, Bhutani D, Zonder J, Azmi AS, Mohammad RM.

Cancer Lett. 2016 Dec 28;383(2):309-317. doi: 10.1016/j.canlet.2016.09.016. Epub 2016 Sep 28.

19.

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.

Kashyap T, Argueta C, Aboukameel A, Unger TJ, Klebanov B, Mohammad RM, Muqbil I, Azmi AS, Drolen C, Senapedis W, Lee M, Kauffman M, Shacham S, Landesman Y.

Oncotarget. 2016 Nov 29;7(48):78883-78895. doi: 10.18632/oncotarget.12428.

20.

The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma.

Diab M, Muqbil I, Mohammad RM, Azmi AS, Philip PA.

J Clin Med. 2016 Jun 16;5(6). pii: E59. doi: 10.3390/jcm5060059. Review.

Supplemental Content

Loading ...
Support Center